MX2024008371A - Compuestos organicos deuterados y usos de los mismos - Google Patents

Compuestos organicos deuterados y usos de los mismos

Info

Publication number
MX2024008371A
MX2024008371A MX2024008371A MX2024008371A MX2024008371A MX 2024008371 A MX2024008371 A MX 2024008371A MX 2024008371 A MX2024008371 A MX 2024008371A MX 2024008371 A MX2024008371 A MX 2024008371A MX 2024008371 A MX2024008371 A MX 2024008371A
Authority
MX
Mexico
Prior art keywords
organic compounds
deuterated organic
compounds
formula
preparation
Prior art date
Application number
MX2024008371A
Other languages
English (en)
Spanish (es)
Inventor
Jordi Serrats
Krishna Vadodaria
Kimberly Vanover
Vikram Sudarsan
David Garvey
Original Assignee
Engrail Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engrail Therapeutics Inc filed Critical Engrail Therapeutics Inc
Publication of MX2024008371A publication Critical patent/MX2024008371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024008371A 2022-01-03 2024-07-02 Compuestos organicos deuterados y usos de los mismos MX2024008371A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263296137P 2022-01-03 2022-01-03
US202263314466P 2022-02-27 2022-02-27
US202263345002P 2022-05-23 2022-05-23
US202263394565P 2022-08-02 2022-08-02
US202263384988P 2022-11-25 2022-11-25
PCT/US2023/010055 WO2023130119A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2024008371A true MX2024008371A (es) 2024-12-06

Family

ID=87000385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008371A MX2024008371A (es) 2022-01-03 2024-07-02 Compuestos organicos deuterados y usos de los mismos

Country Status (10)

Country Link
US (1) US12606523B2 (cg-RX-API-DMAC10.html)
EP (1) EP4460292A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025501411A (cg-RX-API-DMAC10.html)
KR (1) KR20240132477A (cg-RX-API-DMAC10.html)
AU (1) AU2023204433B2 (cg-RX-API-DMAC10.html)
CA (1) CA3242755A1 (cg-RX-API-DMAC10.html)
IL (1) IL313999A (cg-RX-API-DMAC10.html)
MX (1) MX2024008371A (cg-RX-API-DMAC10.html)
TW (1) TW202333671A (cg-RX-API-DMAC10.html)
WO (1) WO2023130119A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025010255A2 (en) 2023-07-02 2025-01-09 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof
WO2026011157A1 (en) 2024-07-05 2026-01-08 Engrail Therapeutics, Inc. Crystalline forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197243A (en) * 1975-04-02 1980-04-08 Yamanouchi Pharmaceutical Co., Ltd. N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives
US4210660A (en) 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
TW212139B (cg-RX-API-DMAC10.html) 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
KR100355130B1 (ko) 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
US5705498A (en) 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CN104744333A (zh) 2013-12-26 2015-07-01 张云 一种奈莫必利的生产方法
US20190343827A1 (en) 2018-05-08 2019-11-14 Izumi Technology, Llc Deuterated analogs of tariquidar
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
US20210017160A1 (en) 2019-07-16 2021-01-21 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
JP2025501410A (ja) 2022-01-03 2025-01-17 エングレイル・セラピューティクス・インコーポレイテッド 重水素化有機化合物およびその使用
WO2025010255A2 (en) 2023-07-02 2025-01-09 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof

Also Published As

Publication number Publication date
US20250011280A1 (en) 2025-01-09
KR20240132477A (ko) 2024-09-03
AU2023204433A1 (en) 2024-07-18
WO2023130119A1 (en) 2023-07-06
IL313999A (en) 2024-08-01
AU2023204433B2 (en) 2026-07-30
EP4460292A4 (en) 2025-07-16
CA3242755A1 (en) 2023-07-06
JP2025501411A (ja) 2025-01-17
TW202333671A (zh) 2023-09-01
EP4460292A1 (en) 2024-11-13
US12606523B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
JOP20200154B1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
CA3242751A1 (en) Deuterated organic compounds and uses thereof
WO2025010259A3 (en) Deuterated organic compounds and uses thereof
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
ATE433447T1 (de) Pyrimiidinverbindungen
MX2020002806A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso.
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
WO2018226622A8 (en) Compounds for treating huntington's disease
MX2020001832A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
GEAP202215303A (en) Chromane monobactam compounds for the treatment of bacterial infections
ECSP078052A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
ECSP078051A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
AU2020231934A8 (en) Compounds useful in HIV therapy
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
TW200738659A (en) Novel compounds
GEAP202115056A (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
PH12021550258A1 (en) Cdk8/19 inhibitors